Last reviewed · How we verify
Belimumab Injection [Benlysta]
Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus.
Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus. Used for Systemic lupus erythematosus (SLE) in patients with active disease despite standard therapy, Lupus nephritis.
At a glance
| Generic name | Belimumab Injection [Benlysta] |
|---|---|
| Sponsor | National University Hospital, Singapore |
| Drug class | BLyS inhibitor monoclonal antibody |
| Target | B-lymphocyte stimulator (BLyS/BAFF) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Belimumab binds to soluble BLyS (also known as BAFF), a cytokine essential for B cell survival and differentiation. By neutralizing BLyS, the drug decreases the survival of autoreactive B cells and plasma cells, leading to reduced production of pathogenic autoantibodies and immune complex formation that drive lupus pathology.
Approved indications
- Systemic lupus erythematosus (SLE) in patients with active disease despite standard therapy
- Lupus nephritis
Common side effects
- Infection (including serious infections)
- Infusion reactions
- Nasopharyngitis
- Bronchitis
- Diarrhea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: